Several CCR scientists will present their research at the AACR Annual Meeting in Washington, D.C., between April 1-5, 2017. Selected oral presentations are listed below. A full list of abstracts can be found on the AACR website.
April 1, 2017
| Time | Title | Authors | Session |
|---|---|---|---|
| 10:15 - 12:15 PM | Immunotherapy combination strategies | James L. Gulley. NCI-CCR | ED18 - Cancer Immunology for the Non-Immunologist: Tutorial |
| 12:00 - 5:00 PM | Constructing a strong career development proposal | Javed Khan. NCI-CCR | PAS01 - Twentieth Annual Grant Writing Workshop, Organized by the Associate Member Council (AMC) |
| 9:00 - 9:25 AM | PARP trapping, replicative damage and Schlafen 11 | Yves G. Pommier. NCI-CCR | ED23 - Synthetic Lethality for treating DNA Repair Defective Human Cancer |
| 9:30 - 9:50 AM | Spontaneous canine malignancies: Models for precision cancer medicine | Amy K. LeBlanc. NCI-CCR | MW04 - Application of Novel Models to Guide Individual Therapies |
April 2, 2017
| Time | Title | Authors | Session |
|---|---|---|---|
| 1:05 - 1:30 PM | Precision medicine: Lung biomarkers | Curtis C. Harris. NCI-CCR | SY37 - Lung Cancer Outcomes: Clinical Implications For Smoking |
| 3:20 - 3:35 PM | CLIC4 is incorporated into extracellular vesicles of murine breast cancer cells and may influence metastatic burden | Alayna B. Craig-Lucas, Vanesa C. Sanchez, Abigail Read, Ji Lou, Anjali Shukla, Stuart H. Yuspa. NCI-CCR | MS.TB04.01 - Niches and Routes of Metastasis |
| 3:35 - 3:50 PM | Directionality of T-cell-mediated cross-protection against the same tumor in lungs versus skin | Jessica J. O'Konek, Elena Ambrosino, Anja Bloom, Liat Izhak, Jay A. Berzofsky, Masaki Terabe. NCI-CCR | MS.IM01.01 - Novel Insights into Mechanisms of Response to Immunotherapy |
| 3:50 - 4:05 PM | Progression from melanocytic nevi to melanoma is associated with increased genomic mutations in a UV-induced mouse model of human melanoma | Helen Michael, Chi-Ping Day, Howard Yang, Aleksandra Michalowski, Maxwell Lee, Glenn Merlino. NCI-CCR | MS.TB01.01 - Animal Models of Human Oncogenesis |
| 4:35 - 4:50 PM | Role of endocytosis in NM23 mediated motility suppression | Imran Khan, Patricia S. Steeg. NCI-CCR | MS.TB04.01 - Niches and Routes of Metastasis |
April 3, 2017
| Time | Title | Authors | Session |
|---|---|---|---|
| 1:35 - 2:00 PM | Microbes in cancer: Friends or foes? | Giorgio Trinchieri. NCI-CCR | SY43 - Inflammation and Cancer |
| 3:15 - 4:00 PM | An Update from the NCI's Acting Director | Douglas R. Lowy. NCI-CCR | LE12 - An Update from the NCI's Acting Director |
| 3:20 - 3:35 PM | Gut microbiome controls liver metastasis | Chi Ma, Qiong Fu, Tim Greten. NCI-CCR | MS.TB06.02 - Tumor and Stromal Cell Interactions |
| 3:20 - 3:35 PM | Polymorphisms in the arntl2 promoter affect breast cancer metastasis susceptibility | Ngoc-Han Ha, Kent Hunter. NCI-CCR | MS.TB04.02 - Early Stages of Metastatic Dissemination |
| 3:35 - 3:50 PM | The antitumor activity of immunotoxins is enhanced by tofacitinib | Nathan Simon1, Antonella Antignani1, Stephen Hewitt1, Massimo Gadina2, Masanori Onda1, Christine Alewine1, David Joseph Fitzgerald1. 1NCI-CCR; 2NIAMS | MS.IM02.02 - Adaptive Immunity in the Tumor Microenvironment |
| 3:50 - 4:05 PM | Exome analysis of known hereditary cancer genes in 122 children with rhabdomyosarcoma | Talia Wegman-Ostrosky1, Rajesh Patidar1, Sivasish Sindiri1, Jack Shern1, Douglas S. Hawkins2, Daniel Catchpoole3, Jun S. Wei1, Stephen Skapek4, Javed Khan1, Douglas R. Stewart1. 1NCI; 2Seattle Children's; 3University of Sydney; 4UT Southwestern Department of Pediatrics | MS.CL02.TB08.01 - Predictors and Drivers of Pediatric Tumors |
| 4:05 - 4:20 PM | Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin’s lymphoma | John Rossi1, Patrick Paczkowski2, Yueh-wei Shen1, Kevin Morse2, Brianna Flynn2, Alaina Kaiser2, Colin Ng2, Kyle Gallatin2, Tom Cain2, Rong Fan3, Sean Mackay2, James Heath4, Steven A. Rosenberg5, James N. Kochenderfer6, Jing Zhou2, Adrian Bot1. 1Kite Pharma; 2IsoPlexis; 3Yale School of Engineering and Applied Science; 4Division of Chemistry and Chemical Engineering, California Institute of Technology; 5Surgery Branch, NCI-CCR; 6Experimental Transplantation and Immunology Branch, NCI-CCR | MS.CL10.01 - Clinical Biomarkers |
| 4:05 - 4:20 PM | Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies | Kristen Zeligs1, Philip M. Arlen2, Kwong Tsang2, Lidia Hernandez3, Massimo Fantini2, Christina M. Annunziata3. 1Walter Reed National Military Medical Center; 2Precision Biologics, Inc.; 3NCI-CCR | MS.IM02.02 - Adaptive Immunity in the Tumor Microenvironment |
| 4:05 - 4:20 PM | Direct regulation of alternative splicing by Smad3 through PCBP1 is essential to the tumor-promoting role of transforming growth factor beta1 | Veenu Tripathi, Katherine M. Sixt, Xuan Xu, Ying E. Zhang. NCI-CCR | MS.MCB01.01 - Breakthroughs in the Control, Function, and Drivers of Oncogenesis |
| 4:05 - 4:20 PM | Comparison of somatic alterations in the genome and transcriptome of 1,705 pediatric leukemia and solid tumors: a report from the Children’s Oncology Group (COG) - NCI TARGET Project | Xiaotu Ma1, Yu Liu1, Yanling Liu1, Michael Edmonson1, Charles Gawad1, Xin Zhou1, Yongjin Li1, Michael Rusch1, John Easton1, Mark Wilkinson1, Leandro C. Hermida2, Sean Davis2, Malcolm Smith2, Jaime Guidry Auvil2, Paul Meltzer2, Ching C. Lau3, Elizabeth Perlman4, John M. Maris5, Soheil Meshinchi6, Stephen P. Hunger5, Daniela S. Gerhard2, Jinghui Zhang1. 1St Jude Children's Research Hospital; 2NCI; 3Texas Children's Cancer and Hematology Centers; 4Ann and Robert H. Lurie Children's Hospital of Chicago; 5Children's Hospital of Philadelphia; 6Fred Hutchinson Cancer Research Center | MS.CL02.TB08.01 - Predictors and Drivers of Pediatric Tumors |
| 4:50 - 5:05 PM | Pharmacokinetic and pharmacodynamic analysis of M7824, a dual anti-PD-L1 and TGFβ TRAP molecule, in the first-in-human phase I dose escalation study | Liang Cao1, Zhigang Kang2, Linghui Li3, Julius Strauss4, Isabelle Dussault3, James Gulley1. 1NCI-CCR; 2Leidos Biomedical Research Inc./NCI-CCR; 3EMD Serono; 4Leidos Biomedical Research Inc. | CTMS02 - Update, Novel Indication, and New Immuno-oncology Clinical Trials |
| 5:15 - 6:00 PM | Lymphoma therapy inspired by functional and structural genomics | Louis M. Staudt. NCI-CCR | Eleventh Annual AACR Princess Takamatsu Memorial Lectureship |
April 4, 2017
| Time | Title | Authors | Session |
|---|---|---|---|
| 3:00 - 5:00 PM | Chair | Christian Hinrichs. NCI-CCR | MS.IM02.01 - Adoptive Cellular Therapy for Cancer |
| 3:05 - 3:20 PM | Dynamic reprogramming of the chromatin landscape in cancer: Studies in real time | Ville Paakinaho, Diego M. Presman, Erin E. Swinstead, Tina B. Miranda, David A. Ball, Tatiana S. Karpova, Gordon L. Hager. NCI-CCR | MS.MCB04.01 - Transcriptional Regulation in Cancer Cells |
| 3:20 - 3:35 PM | Miswired super enhancer logic driving childhood sarcoma | Berkley E. Gryder1, Marco Wachtel2, Hsien-Chao Chou1, Young Song1, Joana Marques2, Beat Schaefer2, Javed Khan1. 1NCI-CCR; 2University Children's Hospital, Zurich, Switzerland | MS.MCB04.01 - Transcriptional Regulation in Cancer Cells |
| 4:20 - 4:35 PM | Regression of metastatic breast cancer after adoptive cell transfer of tumor infiltrating lymphocytes and checkpoint blockade | Nikolaos Zacharakis1, Katarzyna Trebska-McGowan2, Robert Somerville1, Yong-Chen Lu1, Anna Pasetto1, Mary Black1, Harshini Chinnasamy1, Hui Xu1, Jared J. Gartner1, Todd D. Prickett1, Paul F. Robbins1, Steven A. Rosenberg1, Stephanie L. Goff1, Steven A. Feldman1. 1NCI-CCR; 2Virginia Commonwealth University | MS.IM02.01 - Adoptive Cellular Therapy for Cancer |
| 4:20 - 4:35 PM | Impaired PARP1 DNA repair defines chemosensitivity in IDH1 mutant cell | Yanxin Lu, Yang Liu, Yu-Ting Su, Wendy Bautista, Mark R. Gilbert, Jing Wu, Chunzhang Yang. NCI-CCR | MS.ET01.01 - Novel Approaches for Experimental Therapeutics |
April 5, 2017
| Time | Title | Authors | Session |
|---|---|---|---|
| 10:20 - 10:45 AM | Mechanisms of oncogenic signaling and therapeutic resistance in lymphoma revealed by CRISPR-Cas9 screens | Louis M. Staudt. NCI-CCR | SY09 - CRISPR and Functional Genomics |
| 10:50 - 11:15 AM | Defining the limitations of CD19CAR immunotherapy in pediatric ALL and development of effective countermeasures | Terry J. Fry. NCI-CCR | SY20 - CAR T Cell Cancer Immunotherapy: Refinements for B Cell Malignancies and Emerging Opportunities in Solid Tumors |